Suppr超能文献

中国启动了一个提升罕见病医疗水平的试点项目。

China launched a pilot project to improve its rare disease healthcare levels.

作者信息

Cui Yazhou, Zhou Xiaoyan, Han Jinxiang

机构信息

Shandong Academy of Medical Science, Shandong Medical Biotechnological Center, Key Laboratory for Biotech Drugs of the Ministry of Health, Jinan 250062, China.

出版信息

Orphanet J Rare Dis. 2014 Jan 27;9:14. doi: 10.1186/1750-1172-9-14.

Abstract

China is facing the great challenge of serving the world's largest rare disease population. It is necessary to develop a specific medical plan to increase the levels of optimal prevention, diagnosis and treatment of rare diseases under the existing clinical service structures in China. In 2013, China launched its first pilot project focused on 20 representative rare diseases. A national network including approximately 100 provincial or municipal medical centers has been established to enable collaboration on rare diseases across China. The main objectives for this project are to develop and apply medical guidelines and clinical pathways for rare diseases, to establish a rare disease patient registry and data repository system, and to promote molecular testing for rare genetic disorders. This project also emphasizes building close links among the collaborative network, clinicians on the frontlines in basic medical services institutions and rare disease patient organizations. Primarily, this project expects to develop an actionable medical services plan to increase the delivery of quality healthcare for individuals and families living with rare diseases in China within five years.

摘要

中国正面临着为全球最大的罕见病患者群体提供服务的巨大挑战。有必要制定一项专门的医疗计划,以在现有临床服务体系下提高中国罕见病的最佳预防、诊断和治疗水平。2013年,中国启动了首个针对20种具有代表性的罕见病的试点项目。一个包括约100家省级或市级医疗中心的全国性网络已建立起来,以便在中国各地开展罕见病方面的合作。该项目的主要目标是制定并应用罕见病医疗指南和临床路径,建立罕见病患者登记和数据存储系统,并推广罕见遗传性疾病的分子检测。该项目还强调在协作网络、基层医疗服务机构的一线临床医生和罕见病患者组织之间建立紧密联系。该项目主要期望在五年内制定一项可实施的医疗服务计划,以增加为中国罕见病患者及其家庭提供的优质医疗服务。

相似文献

1
China launched a pilot project to improve its rare disease healthcare levels.
Orphanet J Rare Dis. 2014 Jan 27;9:14. doi: 10.1186/1750-1172-9-14.
2
The future of Cochrane Neonatal.
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
4
National Rare Diseases Registry System of China and Related Cohort Studies: Vision and Roadmap.
Hum Gene Ther. 2018 Feb;29(2):128-135. doi: 10.1089/hum.2017.215.
5
Critical Care Network in the State of Qatar.
Qatar Med J. 2019 Nov 7;2019(2):2. doi: 10.5339/qmj.2019.qccc.2. eCollection 2019.
7
Japan as the front-runner of super-aged societies: Perspectives from medicine and medical care in Japan.
Geriatr Gerontol Int. 2015 Jun;15(6):673-87. doi: 10.1111/ggi.12450. Epub 2015 Feb 5.
8
The European Paediatric Rare Tumours Network - European Registry (PARTNER) project for very rare tumors in children.
Pediatr Blood Cancer. 2021 Jun;68 Suppl 4:e29072. doi: 10.1002/pbc.29072. Epub 2021 Apr 29.
9
Designing rare disease care pathways in the Republic of Ireland: a co-operative model.
Orphanet J Rare Dis. 2022 Apr 11;17(1):162. doi: 10.1186/s13023-022-02309-6.
10
The NCI All Ireland Cancer Conference.
Oncologist. 1999;4(4):275-277.

引用本文的文献

1
Rare but not to be overlooked: Epidemiology and strategies for rare dermatological diseases in China.
Intractable Rare Dis Res. 2025 Aug 31;14(3):151-161. doi: 10.5582/irdr.2025.01039.
2
National Rare Diseases Registry System (NRDRS): China's first nation-wide rare diseases demographic analyses.
Orphanet J Rare Dis. 2021 Dec 18;16(1):515. doi: 10.1186/s13023-021-02130-7.
4
A compilation of national plans, policies and government actions for rare diseases in 23 countries.
Intractable Rare Dis Res. 2018 Nov;7(4):213-222. doi: 10.5582/irdr.2018.01085.
5
Comparing regional models of congenital bleeding disorders: preliminary steps in the Italian context.
BMC Res Notes. 2017 Jun 26;10(1):229. doi: 10.1186/s13104-017-2552-6.
6
Fragile X Syndrome: Prevalence, Treatment, and Prevention in China.
Front Neurol. 2017 Jun 6;8:254. doi: 10.3389/fneur.2017.00254. eCollection 2017.
7
Review of 11 national policies for rare diseases in the context of key patient needs.
Orphanet J Rare Dis. 2017 Mar 31;12(1):63. doi: 10.1186/s13023-017-0618-0.
9
Challenges in orphan drug development and regulatory policy in China.
Orphanet J Rare Dis. 2017 Jan 18;12(1):13. doi: 10.1186/s13023-017-0568-6.
10
Orphan drug development in China - Turning challenges into opportunities.
Intractable Rare Dis Res. 2016 Nov;5(4):308-313. doi: 10.5582/irdr.2016.01025.

本文引用的文献

1
Rare diseases research in China: Opportunities, challenges, and solutions.
Intractable Rare Dis Res. 2012 Feb;1(1):10-2. doi: 10.5582/irdr.2012.v1.1.10.
2
Analysis and evaluation of clinical pathways in china.
Stud Health Technol Inform. 2013;192:919.
3
Targeted next-generation sequencing can replace Sanger sequencing in clinical diagnostics.
Hum Mutat. 2013 Jul;34(7):1035-42. doi: 10.1002/humu.22332. Epub 2013 Apr 29.
4
Next generation sequencing in cardiovascular diseases.
World J Cardiol. 2012 Oct 26;4(10):288-95. doi: 10.4330/wjc.v4.i10.288.
7
Rural and urban disparity in health services utilization in China.
Med Care. 2007 Aug;45(8):767-74. doi: 10.1097/MLR.0b013e3180618b9a.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验